Institut Jules Bordet

The Institute Jules Bordet (IJB) is an autonomous comprehensive cancer centre devoted entirely to the fight against cancer. The institute is part of two hospitals networks: the anticancer centres of the Free University of Brussels and IRIS, the network of public hospitals in Brussels. IJB coordinates the “Programme de Soins Oncologique” and is also an active member of the Organisation of European Cancer Institutes (OECI). Its mission is: to provide optimal care to patients, to organise high level teaching activities and to conduct fundamental, translational and clinical research.

The Institute Jules Bordet has an international reputation, especially in breast cancer research. It provides multidisciplinary care to more than 500 new breast patients each year and plays a leading role in translational /clinical research for this disease. In particular, the department of Medical Oncology is actively participating into ~200 clinical trials (35 of Phase I, 80 of Phase II and 78 of Phase III, partly industry sponsored and partly academic trials), some of which are carried out in cooperation with national and international centres, especially in the framework of the EORTC (European Organisation for Research and Treatment of Cancer) and BIG (Breast International Groups).


In EURECA, the IJB ICT department participates in WP4 and WP9 by providing models for EHR data, collected at various key points in the patient‘s clinical process, that were coded and normalised using international coding systems (as LOINC, SNOMED CT, ICD9 and ICDO) for each domain relevant to screening for inclusion in a clinical trial and adverse event reporting. An export of clinical trial databases will be provided for many studies handled by IJB data centres. Moreover, a database of all clinical trials approved by IJB Ethics Committee is also maintained including a description of their eligibility criteria, and will serve as a starting point for providing models for clinical trial description. IJB also contributes to the definition of user’s requirements and to the development and validation of the scenarios concerning improved recruitment, hypothesis generation and protocol feasibility.